CLOV

AI Memo

Clover Health Investments

As of 2026-10-02/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

2027 4.5-Star payment-year economics • 2027-01-01

Base target: $5 / p=45% prob

Biggest risk

Rapid membership growth could outpace medical-cost and administrative-expense discipline. The 2027 cohort and Star-payment benefits may be smaller than anticipated, leaving a growth story with limited margin durability. [#SEC-8K-2026-08-05]

Invalidation

Break below $3 or thesis failure.

What would change my mind?

Q2 revenue rose 56% year over year to $743 million, Medicare Advantage membership rose 48% to 157,309, and Clover reported positive GAAP net income while raising full-year guidance. Sustained medical-cost control and improving cohort economics could support a rerating. [#SEC-8K-2026-08-05]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-02

Base target

p=45%

Bull target

p=30%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Delivery against raised 2026 profitability guidance
Maturing member cohorts and clinical engagement
Q2 revenue rose 56% year over year to $743 million, Medicare Advantage membership rose 48% to 157,309, and Clover reported positive GAAP net income while raising full-year guidance.

BearKey bullets

Failure to achieve raised 2026 revenue, adjusted EBITDA, or GAAP net-income guidance would challenge the rerating thesis.
[#SEC-8K-2026-08-05]
Medical claims and benefit costs could erode profitability despite membership growth.

WatchKey bullets

2027 4.5-Star payment-year economics

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $5 (p=45%)

Target spread vs base: +23% / -35%

Scenario probabilities

Bull Target: $6 (p=30%)Base Target: $5 (p=45%)Bear Target: $3 (p=25%)

Commentary

Company-reported Q2 growth, profitability, and raised guidance support a cautious positive view. The supplied recent-news sample is thin, and the available target lacks an analyst count; no reliable post-print revision series or current options, short-interest, employee, or social measures was supplied. The numeric zero sentiment fields indicate unavailable data, not neutral readings. [#SEC-8K-2026-08-05]

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Delivery against raised 2026 profitability guidance
Maturing member cohorts and clinical engagement

Scenarios

Bull Target (Scenario probability)

$6 / p=30% prob

Base Target (Scenario probability)

$5 / p=45% prob

Bear Target (Scenario probability)

$3 / p=25% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-01-01
2027 4.5-Star payment-year economics
The Q2 earnings exhibit cited the added flexibility of a 4.5-Star payment year in its 2027 outlook. The investment question is whether that benefit translates into durable margins rather than being offset by medical costs or competitive pricing. [#SEC-8K-2026-08-05]
Prob 72.00% • Move 10.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Delivery against raised 2026 profitability guidance
2026-12-31
After reporting Q2 GAAP net income of $28 million and adjusted EBITDA of $41 million, Clover raised full-year guidance to $2.92–$3.00 billion of revenue, $70–$85 million of adjusted EBITDA, and $20–$35 million of GAAP net income. The remaining 2026 results must substantiate those targets as membership grows. [#SEC-8K-2026-08-05]
Prob 68% • Move 12% • Priced-in 60%

Long-term Catalysts

Months to a year

Maturing member cohorts and clinical engagement
2027-12-31
Management attributed its increased confidence in 2027 to cohort development and clinical engagement. Evidence that newer Medicare Advantage members produce stronger economics as they mature would support the longer-term thesis; the outcome remains unproven. [#SEC-8K-2026-08-05]
Prob 62% • Move 15% • Priced-in 50%

Risks

Failure to achieve raised 2026 revenue, adjusted EBITDA, or GAAP net-income guidance would challenge the rerating thesis. [#SEC-8K-2026-08-05]
Medical claims and benefit costs could erode profitability despite membership growth.
Several Form 4 filings show officer open-market sales, including a 300,000-share sale on September 15; these establish trading activity, not a deterioration in operations. [#SEC-FORM4-2026-09-16]
The expected 2027 benefit from cohort maturation and the 4.5-Star payment year may not translate into durable earnings. [#SEC-8K-2026-08-05]

Peers

Symbol	Summary
ABT	Broad health-care reference only. Abbott's device-heavy, large-cap business is not a direct Medicare Advantage operating or valuation comparable.
AXGN	Similar market capitalization in the packet, but a medical-device business rather than a Medicare Advantage insurer; operating read-through is weak.
BFLY	Similar market capitalization in the packet, but its device and imaging exposure makes it an unsuitable direct margin or regulatory benchmark.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

ABT

Broad health-care reference only. Abbott's device-heavy, large-cap business is not a direct Medicare Advantage operating or valuation comparable.

AXGN

Similar market capitalization in the packet, but a medical-device business rather than a Medicare Advantage insurer; operating read-through is weak.

BFLY

Similar market capitalization in the packet, but its device and imaging exposure makes it an unsuitable direct margin or regulatory benchmark.